From Clinical to Non-clinical Outcomes in the Treatment of HIV: An Economic and Organizational Impact Assessment

Overview

Journal Pharmacoecon Open

Date 2024 Nov 12

PMID 39532817

Authors

Ferrario Lucrezia

Lucrezia Ferrario

Barbara Menzaghi

Menzaghi Barbara

Rizzardini Giuliano

Giuliano Rizzardini

Alessandro Roccia

Roccia Alessandro

Elisabetta Garagiola

Garagiola Elisabetta

Daniele Bellavia

Bellavia Daniele

Fabrizio Schettini

Schettini Fabrizio

Emanuela Foglia

Foglia Emanuela

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to define the economic and organizational impacts related to a broader utilization of bictegravir/emtricitabine/alafenamide (BIC/FTC/TAF) in Italian clinical practice.

Methods: A budget impact analysis-representing the evolution of the Italian National Healthcare Service (NHS) healthcare expenditure over 3 years-was developed, considering the overall Italian population treated for human immunodeficiency virus (HIV). Model input variables were treatment history, therapeutic regimen, development of adverse events, achievement of an undetectable viral load and total direct healthcare costs. Besides the BIA, an organizational impact assessment was conducted to determine the impact on the use of healthcare resources, assessing the release of organizational hospital assets, focusing on the management of drug-related adverse events. Data were collected from scientific evidence, Italian national and regional legislations and healthcare professionals' reports. To verify the robustness of the economic and organizational impact assessment, sensitivity analyses were performed.

Results: Results demonstrate economic savings of about 26 million euros in total health spending, assuming a higher penetration rate for BIC/FTC/TAF. This change in the current case mix would lead to a reduction in the specific costs related to adverse event management (0.9 million euros; - 2.09%) and in the medical management of patients (38 million euros; - 7.79%), with a positive impact on the achievement of virological control. From an organizational perspective, a wider use of BIC/FTC/TAF generates a reduction in the utilization of healthcare resources due to a decrease in adverse events and complications. The model estimated a 19.64% reduction in HIV-related inpatient days, which freed up healthcare professional time.

Conclusions: Capable of improving both economic and organizational sustainability for the entire HIV care continuum, BIC/FTC/TAF is an efficient therapeutic strategy for people with HIV.

References

Eron J, Orkin C, Cunningham D, Pulido F, Post F, De Wit S . Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of.... Antiviral Res. 2019; 170:104543. DOI: 10.1016/j.antiviral.2019.104543. View

Lee S, Sinclair E, Hatano H, Hsue P, Epling L, Hecht F . Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging. PLoS One. 2014; 9(2):e89444. PMC: 3937334. DOI: 10.1371/journal.pone.0089444. View

Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A . Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017; 4(5):e195-e204. DOI: 10.1016/S2352-3018(17)30031-0. View

Cahn P, Sierra Madero J, Arribas J, Antinori A, Ortiz R, Clarke A . Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised,.... Lancet. 2018; 393(10167):143-155. DOI: 10.1016/S0140-6736(18)32462-0. View

Mills A, Arribas J, Andrade-Villanueva J, DiPerri G, van Lunzen J, Koenig E . Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2015; 16(1):43-52. DOI: 10.1016/S1473-3099(15)00348-5. View

Samji H, Cescon A, Hogg R, Modur S, Althoff K, Buchacz K . Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013; 8(12):e81355. PMC: 3867319. DOI: 10.1371/journal.pone.0081355. View

Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C . Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS One. 2011; 6(6):e20476. PMC: 3111406. DOI: 10.1371/journal.pone.0020476. View

Mendoza I, Lazaro A, Espinosa A, Sanchez L, Horta A, Torralba M . Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults. PLoS One. 2023; 18(9):e0291480. PMC: 10540944. DOI: 10.1371/journal.pone.0291480. View

Butler K, Anderson S, Hayward O, Jacob I, Punekar Y, Evitt L . Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States. J Manag Care Spec Pharm. 2021; 27(7):891-903. PMC: 10391195. DOI: 10.18553/jmcp.2021.27.7.891. View

10.

Molina J, Ward D, Brar I, Mills A, Stellbrink H, Lopez-Cortes L . Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre,.... Lancet HIV. 2018; 5(7):e357-e365. DOI: 10.1016/S2352-3018(18)30092-4. View

11.

Eron J, Orkin C, Gallant J, Molina J, Negredo E, Antinori A . A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2018; 32(11):1431-1442. PMC: 6039393. DOI: 10.1097/QAD.0000000000001817. View

12.

van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J . Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type.... Clin Infect Dis. 2020; 71(8):1920-1929. PMC: 7643745. DOI: 10.1093/cid/ciz1243. View

13.

Aboud M, Orkin C, Podzamczer D, Bogner J, Baker D, Khuong-Josses M . Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019; 6(9):e576-e587. DOI: 10.1016/S2352-3018(19)30149-3. View

14.

Orkin C, Molina J, Negredo E, Arribas J, Gathe J, Eron J . Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically.... Lancet HIV. 2017; 5(1):e23-e34. DOI: 10.1016/S2352-3018(17)30179-0. View

15.

Trapero-Bertran M, Oliva-Moreno J . Economic impact of HIV/AIDS: a systematic review in five European countries. Health Econ Rev. 2015; 4(1):15. PMC: 4502071. DOI: 10.1186/s13561-014-0015-5. View

16.

Siapka M, Remme M, Obure C, Maier C, Dehne K, Vassall A . Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countries. Bull World Health Organ. 2014; 92(7):499-511AD. PMC: 4121865. DOI: 10.2471/BLT.13.127639. View

17.

Nakagawa F, May M, Phillips A . Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis. 2012; 26(1):17-25. DOI: 10.1097/QCO.0b013e32835ba6b1. View

18.

Humphrey-Murto S, Varpio L, Gonsalves C, Wood T . Using consensus group methods such as Delphi and Nominal Group in medical education research. Med Teach. 2016; 39(1):14-19. DOI: 10.1080/0142159X.2017.1245856. View

19.

Sax P, Rockstroh J, Luetkemeyer A, Yazdanpanah Y, Ward D, Trottier B . Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2020; 73(2):e485-e493. PMC: 8282313. DOI: 10.1093/cid/ciaa988. View

20.

Cahn P, Sierra Madero J, Arribas J, Antinori A, Ortiz R, Clarke A . Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. J Acquir Immune Defic Syndr. 2019; 83(3):310-318. PMC: 7043729. DOI: 10.1097/QAI.0000000000002275. View